ABOUT US
MC2 Therapeutics is a commercial stage pharmaceutical company committed to optimize the treatment experience and address unmet needs for patients with autoimmune and chronic inflammatory conditions through innovative best-in-class or first-in-class topical therapies tailored for fast and safe relief of symptoms in formulations that patients prefer to use in daily routines. Read more about MC2 Therapeutics.
Platform
Our PAD™ Technology offers a number of unique advantages in the development of potent innovative new topical therapies for auto-immune and inflammatory conditions. Read more about our platform.
Pipeline
MC2 Therapeutics is uncovering new topical therapies within the field of autoimmune and inflammatory conditions. We are proud to take leadership in setting a new standard powered by our PAD™ Technology, our research into the root causes of poorly understood autoimmune and chronic inflammatory conditions and our ability to effectively execute on development of best in class or first in class innovative topical therapies. All exemplified by our recently US FDA approved Wynzora® Cream for treatment of plaque psoriasis. Read more about our pipeline.
